Clinical Trial Update: Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating liraglutide 3.0 mg for weight management in overweight/obesity with type 2 diabetes on basal insulin; study completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2019-11-27